The Board of the National Center for Cancer Research (CNIO), which is the largest cancer research center in Spain, reached a unanimous decision to cease all contracts with Gedosol SL, a company implicated in an alleged corruption scandal that may have siphoned off up to 30 million euros in public funds. This decision came as a response to growing concerns regarding misuse of resources in the institution, suggesting a systemic issue within the dealings of the center.

The board includes representatives from the central government, multiple autonomous communities governed by the People's Party (PP), and various private foundations such as Cris Against Cancer and the BBVA Foundation. This diverse composition helps ensure that the decision reflects a broad consensus on the integrity of operations at the CNIO, emphasizing a commitment to transparency and accountability in the management of public funds.

Furthermore, in light of the current management absence, the board has empowered the acting scientific director with signing authority to maintain operational continuity while safeguarding against any further fallout from the scandal. This proactive move aims to restore confidence in the CNIO’s governance and to prevent any potential paralysis in cancer research activities resulting from the ongoing investigations.